Start Over

Venous thromboembolism in metastatic pancreatic cancer.

Authors :: Laderman L
Sreekrishnanilayam K
Pandey RK
Handorf E
Blumenreich A
Sorice KA
Lynch SM
Cheema K
Nagappan L
Sosa IR
Dotan E
Vijayvergia N
Source :: European journal of haematology [Eur J Haematol] 2023 Jun; Vol. 110 (6), pp. 706-714. Date of Electronic Publication: 2023 Mar 30.
Publication Year :: 2023
Abstract: Background: Pancreatic cancer (PC) carries a high risk of venous thromboembolism (VTE). Several risk assessment models (RAMs) predict benefit of thromboprophylaxis in solid tumors; however, none are verified in metastatic pancreatic cancer (mPC).<br />Methods: A retrospective mPC cohort treated at an academic cancer center from 2010 to 2016 was investigated for VTE incidence (VTEmets). Multivariable regression analysis was used to assess multiple VTE risk factors. Overall survival (OS) was compared between mPC groups with and without VTE. Survival was analyzed using Kaplan-Meier survival plots and Cox proportional hazards regressions.<br />Results: 400 mPC patients (median age 66; 52% males) were included. 87% had performance status of ECOG 0-1; 70% had advanced stage at PC diagnosis. Incidence of VTEmets was 17.5%; median time of occurrence 3.48 months after mPC diagnosis. Survival analysis started at median VTE occurrence. Median OS was 10.5 months in VTEmets vs. 13.4 in non-VTE group. Only advanced stage (OR 3.7, p = .001) correlated with increased VTE risk.<br />Conclusions: The results suggest mPC carries a significant VTE burden. VTE predicts poor outcomes from the point of median VTE occurrence. Advanced stage disease is the strongest risk factor. Future studies are needed to define risk stratification, survival benefit, and choice of thromboprophylaxis.<br /> (© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)